Dr. David Kimberlin holds the Sergio Stagno Endowed Chair in Pediatric Infectious Diseases at the University of Alabama at Birmingham, where he is Vice Chair for Clinical and Translational Research and Co-Director of the Division of Pediatric Infectious Diseases. Dr. Kimberlin also is the Principal Investigator for the Collaborative Antiviral Study Group (CASG). Funded continuously by NIH/NIAID/DMID since the early 1970s, the CASG is a network of pediatric academic medical centers that evaluates antiviral therapeutics in rare diseases with a large unmet medical need, including neonatal herpes simplex virus (HSV) infections, congenital cytomegalovirus (CMV) disease, congenital Zika syndrome, neonatal and infantile influenza infection, and neonatal enteroviral sepsis syndrome. Current studies are evaluating novel treatment approaches for neonatal HSV, new antiviral drugs for congenital CMV, longterm benefit of antiviral therapy in congenital CMV, and natural history studies of acute flaccid myelitis and neonatal enteroviral sepsis. These studies build upon previous CASG studies conducted by Dr. Kimberlin that have defined the standard of care for the treatment of neonatal HSV and congenital CMV infections.